van Houte Hans sold $116K of NRIX
van Houte Hans (Chief Financial Officer) sold 4,761 shares of Nurix Therapeutics, Inc. (NRIX) at an average of $24.36 ($23.89–$24.65, $0.12M total) across 2 trades on 2026-08-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on insider selling activity (4,761 shares) and the execution price range ($23.8911 to $24.6474) but does not include new operating or financial guidance.
Market read
Traders may note the insider sale, but the 10b5-1 framing suggests limited incremental information for valuation.
What to watch
Insider sales can be driven by liquidity needs or tax planning; without additional context (e.g., other concurrent insider buys), the market impact is usually limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Nurix Therapeutics, Inc.
Ticker impact
Nurix Therapeutics CFO van Houte Hans filed a Form 4 selling 4,761 shares in open-market trades on 2026-08-04 under a 10b5-1 plan.
Likely minimal, unless investors interpret the sale as a broader confidence signal.
The filing discloses transaction size, price range, and that it was executed under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No sector-wide implications; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be mechanically scheduled and not a bearish signal.
Key entities
- issuerNurix Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insidervan Houte Hans
Nurix CFO who sold shares via open-market transactions under a 10b5-1 plan.
